CervoMed Inc.
General ticker "CRVO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $57.5M (TTM average)
CervoMed Inc. does not follow the US Stock Market performance with the rate: -24.4%.
Estimated limits based on current volatility of 3.8%: low 2.96$, high 3.19$
Factors to consider:
- Total employees count: 15 (0.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Failure to achieve profitability, Capital raising failure, Labor/talent shortage/retention, Regulatory and compliance
- Current price 17.9% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.03$, 11.48$]
- 2026-12-31 to 2027-12-31 estimated range: [3.88$, 10.86$]
Financial Metrics affecting the CRVO estimates:
- Negative: with PPE of -2.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: 69.38 < Shareholder equity ratio, % of 79.65 <= 81.92
Short-term CRVO quotes
Long-term CRVO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $7.14MM | $9.74MM | $4.01MM |
| Operating Expenses | $14.96MM | $27.97MM | $32.30MM |
| Operating Income | $-7.81MM | $-18.23MM | $-28.29MM |
| Non-Operating Income | $5.64MM | $1.94MM | $1.33MM |
| R&D Expense | $8.44MM | $18.80MM | $21.82MM |
| Income(Loss) | $-2.17MM | $-16.29MM | $-26.97MM |
| Net Income(Loss)* | $-2.17MM | $-16.29MM | $-26.97MM |
| Stockholders Equity | $7.38MM | $39.20MM | $18.22MM |
| Assets | $9.97MM | $43.08MM | $22.88MM |
| Operating Cash Flow | $-7.45MM | $-16.53MM | $-23.45MM |
| Investing Cash Flow | $0.00MM | $-28.66MM | $18.10MM |
| Financing Cash Flow | $11.15MM | $46.40MM | $4.59MM |
| Earnings Per Share** | $-0.82 | $-2.02 | $-2.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.